Embecta Corp. (EMBC) vs Turn Therapeutics Inc. (TTRX)
A side-by-side comparison of Embecta Corp. and Turn Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
EMBC
Embecta Corp.
$5.95HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
TTRX
Turn Therapeutics Inc.
$11.64HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Total return — EMBC vs TTRX
growth of $100 · dividends reinvested · last 1yEMBC -56.1% (-56.1%/yr)TTRX +76.6% (+76.6%/yr)TTRX compounded faster over this window
EMBC TTRX
EMBC vs TTRX: by the numbers
- •EMBC is the larger company ($353M vs $347M market cap).
- •EMBC is profitable (8.59% net margin) while TTRX runs a net loss (0.00%).
- •EMBC pays a dividend (5.44% yield), while TTRX has no payments in the available dividend history.
Metrics side by side
Valuation
| Metric | EMBC | TTRX |
|---|---|---|
| P/E ratio | 4.02 | N/A |
| Forward P/E | 3.38 | N/A |
| P/S ratio | 0.35 | N/A |
| P/B ratio | N/A | 504.79 |
| EV / EBITDA | 5.38 | N/A |
| FCF yield | 46.63% | N/A |
Profitability
| Metric | EMBC | TTRX |
|---|---|---|
| Gross margin | 59.89% | 0.00% |
| Operating margin | 24.85% | 0.00% |
| Net margin | 8.59% | 0.00% |
| ROE | N/A | -1229.58% |
| ROIC | 17.99% | -84.66% |
Dividends
| Metric | EMBC | TTRX |
|---|---|---|
| Dividend yield | 5.44% | N/A |
| Payout ratio | 21.62% | N/A |
Growth (annualized)
| Metric | EMBC | TTRX |
|---|---|---|
| Revenue CAGR (5Y) | -0.09% | N/A |
| EPS CAGR (5Y) | -26.22% | N/A |
| FCF CAGR (5Y) | -16.77% | N/A |
Frequently asked
- Does EMBC or TTRX pay a bigger dividend?
- EMBC pays a dividend (5.44% yield), while TTRX has no payments in the available dividend history.
- Is EMBC or TTRX more profitable?
- EMBC runs the higher net margin — EMBC at 8.59% versus TTRX at 0.00%.
Go deeper
Dig into the metrics
Embecta P/E ratioEmbecta dividend yieldEmbecta ROETurn Therapeutics ROEEmbecta operating marginTurn Therapeutics operating marginEmbecta revenue growthTurn Therapeutics revenue growthEmbecta free cash flowTurn Therapeutics free cash flow
Embecta & Turn Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.